Lassman, A. B., van den Bent, M. J., Gan, H. K., Reardon, D. A., Kumthekar, P., Butowski, N., . . . Merrell, R. (2019). Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: Results from an international phase I multicenter trial. Neuro Oncol.
Stile di citazione ChicagoLassman, Andrew B., et al. "Safety and Efficacy of Depatuxizumab Mafodotin + Temozolomide in Patients With EGFR-amplified, Recurrent Glioblastoma: Results From an International Phase I Multicenter Trial." Neuro Oncol 2019.
Citazione MLALassman, Andrew B., et al. "Safety and Efficacy of Depatuxizumab Mafodotin + Temozolomide in Patients With EGFR-amplified, Recurrent Glioblastoma: Results From an International Phase I Multicenter Trial." Neuro Oncol 2019.